Advertisement

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

Scott R. Daigle, Edward J. Olhava, Carly A. Therkelsen, Aravind Basavapathruni, Lei Jin, P. Ann Boriack-Sjodin, Christina J. Allain, Christine R. Klaus, Alejandra Raimondi, Margaret Porter Scott, Nigel J. Waters, Richard Chesworth, Mikel P. Moyer, Robert A. Copeland, Victoria M. Richon and Roy M. Pollock

Article Information

Citation 
vol. 122 no. 6 1017-1025
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted April 16, 2013
  • Accepted May 23, 2013
  • Published online August 8, 2013.

Article Versions


Contributors 
  • Scott R. Daigle, Epizyme, Inc., Cambridge, MA
  • Edward J. Olhava, Epizyme, Inc., Cambridge, MA
  • Carly A. Therkelsen, Epizyme, Inc., Cambridge, MA
  • Aravind Basavapathruni, Epizyme, Inc., Cambridge, MA
  • Lei Jin, Epizyme, Inc., Cambridge, MA
  • P. Ann Boriack-Sjodin, Epizyme, Inc., Cambridge, MA
  • Christina J. Allain, Epizyme, Inc., Cambridge, MA
  • Christine R. Klaus, Epizyme, Inc., Cambridge, MA
  • Alejandra Raimondi, Epizyme, Inc., Cambridge, MA
  • Margaret Porter Scott, Epizyme, Inc., Cambridge, MA
  • Nigel J. Waters, Epizyme, Inc., Cambridge, MA
  • Richard Chesworth, Epizyme, Inc., Cambridge, MA
  • Mikel P. Moyer, Epizyme, Inc., Cambridge, MA
  • Robert A. Copeland, Epizyme, Inc., Cambridge, MA
  • Victoria M. Richon, Epizyme, Inc., Cambridge, MA
  • Roy M. Pollock, Epizyme, Inc., Cambridge, MA

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output